165950-06-1

Usage

Uses

Used in Pharmaceutical Industry:
5-(tert-Butoxycarbonylamino-methyl)-2-methyl-benzoic acid is used as a building block for the synthesis of pharmaceutical compounds due to its unique structural features, which may contribute to the development of new drugs with specific therapeutic properties.
Used in Organic Synthesis:
In the field of organic synthesis, 5-(tert-Butoxycarbonylamino-methyl)-2-methyl-benzoic acid serves as an intermediate or a precursor for the creation of more complex organic molecules, potentially leading to advancements in material science and chemical research.
(Note: The specific applications and uses mentioned are hypothetical and would require further research and testing to validate their practicality and effectiveness.)

Upstream product

• 1184301-84-5 methyl 5-(((tert-butoxycarbonyl)amino)methyl)-2-methylbenzoate 
• 77324-87-9 methyl 2-methyl-5-nitrobenzoate 
• 18595-12-5 methyl 5-amino-2-methylbenzoate 
• 1975-52-6 5-nitro-o-toluic acid 

Downstream Products

• 1184301-87-8 5-N-tert-butoxycarbonylmethylamino-2-methyl-N-[(R)-1-(1-naphthyl)ethyl]benzamide 

Relevant academic research and scientific papers

PHTALAZINONE DERIVATIVES AS MPEGS -1 INHIBITORS

The present patent application is directed to bicyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (m PGES-1) enzyme and are theref

COMPOUNDS AND METHODS FOR TREATING RESPIRATORY DISEASES

Described herein are compounds and compositions, and methods for using the compounds and compositions, for treating respiratory diseases and illness, such as severe acute respiratory syndrome (SARS).

Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome - Coronavirus papain-like protease

We describe here the design, synthesis, molecular modeling, and biological evaluation of a series of small molecule, nonpeptide inhibitors of SARS-CoV PLpro. Our initial lead compound was identified via high-throughput screening of a diverse chemical library. We subsequently carried out structure - activity relationship studies and optimized the lead structure to potent inhibitors that have shown antiviral activity against SARS-CoV infected Vero E6 cells. Upon the basis of the X-ray crystal structure of inhibitor 24-bound to SARS-CoV PLpro, a drug design template was created. Our structure-based modification led to the design of a more potent inhibitor, 2 (enzyme IC50 = 0.46 μM; antiviral EC50 = 6 μM). Interestingly, its methylamine derivative, 49, displayed good enzyme inhibitory potency (IC50 = 1.3 μM) and the most potent SARS antiviral activity (EC50 = 5.2 μM) in the series. We have carried out computational docking studies and generated a predictive 3D-QSAR model for SARS-CoV PLpro inhibitors.